search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
TECH INSIGHT LASER FABRIC


Healing light


Using painless blasts of laser light from a wearable fabric, French scientists are now able to treat painful skin irritations


A


group of French Scientists have developed a wearable


laser for clinics to treat enflamed skin or lesions. The laser, designed as a


knitted fabric, can be applied to any contour of the skin to provide fast, almost painless relief to those with chronic skin conditions such as acne, Actinic Keratosis, Paget’s disease psoriasis, and other diseases such as baby jaundice. Developed at Texinov Medical


Textiles in collaboration with the pan-European health consortium Phos-Istos, the knitted laser fabric, dubbed ‘Fluxmedicare’ was initially designed to improve the treatment of Actinic Keratosis – rough, scaly patches on the skin that develop from years of exposure to the sun. It has since been heralded as a ‘miracle cure’ by users in clinical trials, and is set to become the quickest available device for eradicating a variety of unwanted skin conditions with no side effects. The team at Phos- Istos expects to have the Fluxmedicare ready for commercial uptake in April. The treatment works by


first covering the affected area with a ‘photosensitiser’ cream before wrapping the skin with the light-emitting textile. Optical fibres knitted into the fabric then speed up the reaction between oxygen and photosensitiser cream beneath the skin.


‘Fluxmedicare is


unprecedented in the field of treating skin conditions,’ said Dr Nadege Boucard, R&D general manager at Texinov. ‘Since the lighting textile wraps around the unique, individual contours of a patient, the


42 Electro Optics March 2018


emitted light in our device is the same at every part of the body under treatment, meaning the beams are homogenous.’ Light has been used to treat skin ailments, such as Actinic Keratosis, before in the form of Photo Dynamic Therapy (PDT), where a patient would need to stand under a lamp and be blasted with high-intensity light from a flat pane, causing severe pain and even redness to the skin. ‘Previous PDT was


unsatisfactory in many ways.’ Boucard said, ‘Not only did patients report a pain ranking of at least seven out of 10 as well as burns and redness persisting for several days, but also, coming from a flat source, a lot of the emitted light was lost.’


“The fact that we had a near 90 per cent drop in pain levels… and the same efficacy, was really promising”


During the clinical trials of


the Fluxmedicare device with Inserm Onco Thai Lab-Chru Lille and Klinikum Vest in Germany, patients reported an average pain ranking between 0 and 1 out of ten. ‘The fact that we had a near 90 per cent drop in pain levels compared to the previous technology, and the same efficacy was really promising,’ said Boucard. ‘Fluxmedicare is easy to use for both the patient and the clinician: since you don’t need to be protected from the laser treatment, you can put your feet up and watch TV during the treatment.’ Costing around a third


of the €15,000 price tag of the old technology, the new Fluxmedicare device comes relatively cheaply for clinics,


The wearable Fluxmedicare fabric can cover any contour of skin and uses homogenous laser light to treat irritable skin conditions in a virtually painless procedure


as no lamp, protective gear or a dedicated set up within a hospital room or dermatologist’s surgery is required. ‘The Fluxmedicare device is


flexible and mobile so a number of patients can be treated simultaneously. In the future we hope to treat people in their own homes. The implied healthcare savings are substantial,’ Boucard commented. The Phos-Istos consortium


secured a grant of €2,390,000 from the European Commission under the CIP funding


programme, and is comprised of participants from five European countries: France (Institut National de la Sante et de la Recherche Medicale, Centre Hospitalier de Lille, EREO Sas, Ecole Nationale Superieure Arts Industries Textiles, Universite de Lille II – Droit et Sante, Deltaval Sarl); Germany (Klinikum Vest); Finland (Fluence Therapeutics, Modulight); Italy (Consorzio per la Promozione della Cultura Plastica Proplast) and the Netherlands (Reden). EO


@electrooptics | www.electrooptics.com


Texinov Medical Textiles


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44